Miranda Mariska, Rozali Esdy, Khanna Kum Kum, Al-Ejeh Fares
QIMR Berghofer Medical Research Institute, Herston QLD, Australia.
Oncoscience. 2015 Feb 20;2(2):99-101. doi: 10.18632/oncoscience.135. eCollection 2015.
The MEK5-ERK5 pathway is a mammalian mitogen-activated protein (MAP) kinase cascade that is not well studied compared to other MAP kinase cascades. Two independent studies by Al-Ejeh et al. and Ortiz-Ruiz et al. published in Oncotarget last year concluded that ERK5 is an attractive target in triple negative breast cancer. In this perspective, we briefly describe the findings of these studies and propose the use of pharmacological inhibition of ERK5 in combination with chemotherapy against triple negative breast cancer because MEK5-ERK5 overexpression associates with poor survival of patients treated with chemotherapy.
与其他丝裂原活化蛋白（MAP）激酶级联反应相比，MEK5 - ERK5信号通路作为一种哺乳动物的MAP激酶级联反应，目前尚未得到充分研究。Al - Ejeh等人和Ortiz - Ruiz等人去年发表在《肿瘤靶向》杂志上的两项独立研究得出结论，ERK5是三阴性乳腺癌中一个有吸引力的靶点。从这个角度来看，我们简要描述了这些研究的结果，并提出将ERK5的药理学抑制与化疗联合用于治疗三阴性乳腺癌，因为MEK5 - ERK5的过表达与接受化疗患者的不良生存率相关。
